ES2398637T3 - Granulado molido y seco y procedimientos - Google Patents

Granulado molido y seco y procedimientos Download PDF

Info

Publication number
ES2398637T3
ES2398637T3 ES11157456T ES11157456T ES2398637T3 ES 2398637 T3 ES2398637 T3 ES 2398637T3 ES 11157456 T ES11157456 T ES 11157456T ES 11157456 T ES11157456 T ES 11157456T ES 2398637 T3 ES2398637 T3 ES 2398637T3
Authority
ES
Spain
Prior art keywords
granulate
particle size
dried
wet
micrometers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11157456T
Other languages
English (en)
Spanish (es)
Inventor
Sara J. Chastain
Walid Habib
Derek Moe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cima Labs Inc
Original Assignee
Cima Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cima Labs Inc filed Critical Cima Labs Inc
Application granted granted Critical
Publication of ES2398637T3 publication Critical patent/ES2398637T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Processing Of Solid Wastes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Glanulating (AREA)
  • Materials Applied To Surfaces To Minimize Adherence Of Mist Or Water (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
ES11157456T 2005-08-30 2006-08-29 Granulado molido y seco y procedimientos Active ES2398637T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US71258005P 2005-08-30 2005-08-30
US712580P 2005-08-30
US507240 2006-08-21
US11/507,240 US20070048373A1 (en) 2005-08-30 2006-08-21 Dried milled granulate and methods

Publications (1)

Publication Number Publication Date
ES2398637T3 true ES2398637T3 (es) 2013-03-20

Family

ID=37804492

Family Applications (3)

Application Number Title Priority Date Filing Date
ES11157456T Active ES2398637T3 (es) 2005-08-30 2006-08-29 Granulado molido y seco y procedimientos
ES10001313T Active ES2379333T3 (es) 2005-08-30 2006-08-29 Granulado secado y molido, y métodos
ES06813925T Active ES2339979T3 (es) 2005-08-30 2006-08-29 Granulado molido seco y metodos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES10001313T Active ES2379333T3 (es) 2005-08-30 2006-08-29 Granulado secado y molido, y métodos
ES06813925T Active ES2339979T3 (es) 2005-08-30 2006-08-29 Granulado molido seco y metodos.

Country Status (12)

Country Link
US (1) US20070048373A1 (fr)
EP (3) EP2359811B1 (fr)
JP (1) JP5144519B2 (fr)
AT (2) ATE539739T1 (fr)
CA (1) CA2621079C (fr)
DE (1) DE602006012503D1 (fr)
DK (1) DK2198855T3 (fr)
ES (3) ES2398637T3 (fr)
HK (3) HK1111622A1 (fr)
MX (1) MX2008002779A (fr)
PT (1) PT2198855E (fr)
WO (1) WO2007027720A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US7485319B2 (en) * 2003-07-25 2009-02-03 Warner Chilcott Company, Inc. Doxycycline metal complex in a solid dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US7883039B2 (en) * 2007-02-27 2011-02-08 Collette Nv Continuous granulating and drying apparatus including measurement units
US8173169B2 (en) * 2007-07-11 2012-05-08 Hikma Pharmaceuticals Formulation and process for the preparation of modafinil
CN102639118B (zh) 2009-07-22 2015-07-29 格吕伦塔尔有限公司 氧化稳定的抗干扰剂型
ES2668203T3 (es) * 2009-12-02 2018-05-17 Adare Pharmaceuticals S.R.L. Microcápsulas de fexofenadina y composiciones que las contienen
TR201000688A2 (tr) * 2010-01-29 2011-08-22 B�Lg�� Mahmut Aktif madde olarak sefaklor ve klavulanik asit içeren efervesan formülasyonlar.
FR2959130A1 (fr) * 2010-04-21 2011-10-28 Sanofi Aventis Procede de preparation de compositions pharmaceutiques destinees a l'administration par voie orale comprenant un ou plusieurs principes actifs et les compositions les comprenant.
JP6133009B2 (ja) * 2010-08-11 2017-05-24 協和発酵キリン株式会社 トピラマート顆粒
CN103269688A (zh) 2010-09-02 2013-08-28 格吕伦塔尔有限公司 包含无机盐的抗破碎剂型
TR201009396A2 (tr) * 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Desloratadin granüller
KR101380836B1 (ko) * 2011-01-18 2014-04-09 한국기계연구원 상온진공과립분사 공정을 위한 취성재료 과립 및 이를 이용한 코팅층의 형성방법
JP5830412B2 (ja) * 2011-03-02 2015-12-09 ライオン株式会社 水難溶性薬物と賦形剤との粉砕物の製造方法、造粒粒子の製造方法、錠剤の製造方法
WO2013017242A1 (fr) 2011-07-29 2013-02-07 Grünenthal GmbH Comprimé anti-manipulation permettant une libération immédiate de médicament
NO2736495T3 (fr) 2011-07-29 2018-01-20
AR090695A1 (es) 2012-04-18 2014-12-03 Gruenenthal Gmbh Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis
WO2014207769A1 (fr) 2013-06-27 2014-12-31 Mylan Laboratories Ltd Procédé pour la préparation de népafénac
KR20160031526A (ko) 2013-07-12 2016-03-22 그뤼넨탈 게엠베하 에틸렌-비닐 아세테이트 중합체를 함유하는 템퍼 내성 투여형
JP6480936B2 (ja) * 2013-11-26 2019-03-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング クライオミリングによる粉末状医薬組成物の調製
CA2998259A1 (fr) 2015-09-10 2017-03-16 Grunenthal Gmbh Protection contre un surdosage par voie orale a l'aide de formulations a liberation immediate dissuasives d'abus
MX2016013830A (es) * 2015-10-27 2017-05-10 Shinetsu Chemical Co Eter de celulosa porosa no ionico soluble en agua que tiene excelente solubilidad y metodo para producir el mismo.
US20220362191A1 (en) * 2021-05-12 2022-11-17 Spectrix Therapeutics, LLC Compositions and methods

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234957A (en) * 1991-02-27 1993-08-10 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
IL92343A0 (en) * 1988-12-20 1990-07-26 Gist Brocades Nv Granulate for multiparticulate controlled release oral compositions,their preparation and oral pharmaceutical compositions containing them
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
AU5140893A (en) * 1992-09-30 1994-04-26 Ascent Pharmaceuticals, Inc. Calcium polycarbophil sprinkle
US5503846A (en) * 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
US6077533A (en) * 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
US6039275A (en) * 1996-07-04 2000-03-21 Holland Sweetener Company V.O.F. Aspartame powders for powder mixtures
ES2296331T3 (es) * 1997-04-01 2008-04-16 Cima Labs Inc. Envase de tipo blister y comprimido envasado.
US6024981A (en) * 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
JPH1121236A (ja) * 1997-07-01 1999-01-26 Ohara Yakuhin Kogyo Kk ロキソプロフェン・ナトリウム固形製剤
US6387410B1 (en) * 1998-09-10 2002-05-14 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
US6740341B1 (en) * 1998-11-25 2004-05-25 Cima Labs Inc. Taste masking rapid release coating system
DE19859636A1 (de) * 1998-12-23 2000-06-29 Hexal Ag Kontrolliert freisetzende pharmazeutische Zusammensetzung mit Tilidinmesylat als Wirkstoff
PT1207860E (pt) * 1999-09-02 2008-01-24 Nostrum Pharmaceuticals Inc Formulação de peletes de libertação controlada
ES2281527T3 (es) * 2001-05-25 2007-10-01 Cephalon, Inc. Formulaciones farmaceuticas solidas que comprenden modafinilo.
US7323192B2 (en) * 2001-09-28 2008-01-29 Mcneil-Ppc, Inc. Immediate release tablet
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
US6827946B2 (en) * 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
US20050065183A1 (en) * 2003-07-31 2005-03-24 Indranil Nandi Fexofenadine composition and process for preparing
US7207505B2 (en) * 2004-06-04 2007-04-24 Bender Martin P Method for producing small granules

Also Published As

Publication number Publication date
ES2379333T3 (es) 2012-04-25
HK1160010A1 (en) 2012-08-10
EP2359811B1 (fr) 2012-11-14
US20070048373A1 (en) 2007-03-01
EP1919454B1 (fr) 2010-02-24
DE602006012503D1 (de) 2010-04-08
WO2007027720A3 (fr) 2007-08-02
EP2198855A1 (fr) 2010-06-23
MX2008002779A (es) 2008-04-07
JP2009505798A (ja) 2009-02-12
CA2621079C (fr) 2014-02-18
ATE539739T1 (de) 2012-01-15
EP1919454A2 (fr) 2008-05-14
ES2339979T3 (es) 2010-05-27
HK1111622A1 (en) 2008-08-15
EP2359811A1 (fr) 2011-08-24
CA2621079A1 (fr) 2007-03-08
PT2198855E (pt) 2012-03-19
JP5144519B2 (ja) 2013-02-13
EP2198855B1 (fr) 2012-01-04
WO2007027720A2 (fr) 2007-03-08
HK1145146A1 (en) 2011-04-08
DK2198855T3 (da) 2012-04-02
ATE458475T1 (de) 2010-03-15

Similar Documents

Publication Publication Date Title
ES2398637T3 (es) Granulado molido y seco y procedimientos
ES2741800T3 (es) Formulación de acetato de abiraterona
ES2398643T3 (es) Composiciones farmacéuticas mejoradas para fármacos escasamente solubles
ES2687751T3 (es) Tratamiento de enfermedades respiratorias
ES2384109T3 (es) Formas farmacéuticas con propiedades farmacocinéticas mejoradas
TWI428333B (zh) 醫藥組合物
ES2529570T3 (es) Formulaciones multiparticuladas de pantoprazol
EP2679219A1 (fr) Procédé de production d'une particule de composé organique finement pulvérisée
ES2922206T3 (es) Formulaciones de polvo seco para la inhalación
ES2764849T5 (es) Composiciones de tabletas que se desintegran por vía oral que contienen corticosteroides para la esofagitis eosinofílica
US10292990B2 (en) Abiraterone steroid formulation
CN112972405B (zh) 一种他达拉非冻干口腔崩解片及其制备方法
ES2804702T3 (es) Composiciones farmacéuticas secas que comprenden nanopartículas de agente activo unidas a partículas de portador
EP1753400A2 (fr) Forme de dosage de ziprasidone
ES2429436T3 (es) Preparaciones de liberación lenta y procedimiento para la producción de las mismas
JP2015537013A (ja) 速崩性錠剤
WO2013117793A1 (fr) Composition pharmaceutique solide de cilostazol